ESC 365 - Lp(a) as target in cardiovascular prevention: Why worry and how to assess?

Open Access

Lp(a) as target in cardiovascular prevention: Why worry and how to assess?

Session: Lp(a), a new lipid frontier in CV risk management & target for therapy

Topic: Lipids

Speaker: Professor P. Kamstrup (Copenhagen, DK)

Organised by PACE-CME, supported by Novartis and Sanofi in the form of an educational grant

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Pia Kamstrup

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 presentations

0 follower

4 more presentations in this session

Lp(a): The new kid in lipid management

Speaker: Professor E. Stroes (Amsterdam, NL)

Novel strategies to lower Lp(a) What are the emerging insights & therapies?

Speaker: Professor S. Tsimikas (La Jolla, US)

ASCVD risk reduction for patients with high Lp(a) in 2020: is there a role for PCSK9 inhibition?

Speaker: Professor V. Bittner (Birmingham, US)

Discussion.

Speaker: Professor E. Stroes (Amsterdam, NL)

Access the full session

Lp(a), a new lipid frontier in CV risk management & target for therapy

Speakers: Professor P. Kamstrup, Professor E. Stroes, Professor S. Tsimikas, Professor V. Bittner, Professor E. Stroes

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources